Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis
By Colin Kellaher
Pacira BioSciences has won a key U.S. Food and Drug Administration designation for its PCRX-201 gene-therapy product candidate for the treatment of osteoarthritis of the knee.
Pacira on Wednesday said the FDA granted regenerative-medicine-advanced-therapy, or RMAT, designation to PCRX-201, marking the agency's first-ever RMAT designation for a gene-therapy product candidate in osteoarthritis.
The FDA's RMAT designation offers eligibility for expedited development and regulatory review of product candidates, including earlier and more frequent consultation with the agency, and the potential for accelerated approval.
Tampa, Fla., pain-management company Pacira said the PCRX-201 designation is supported by encouraging preliminary data from a 72-patient phase 1 study.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 13, 2024 07:56 ET (11:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks